Table 2 Response rates to olutasidenib and azacitidine combination treatment
Response rates | R/R AML (N = 67) | R/R AML excluding prior olutasidenib (N = 51) |
|---|---|---|
CR rate | ||
Response rate, n (%) [95% CI] | 18 (27%) [95% CI 16.8 - 39.1] | 16 (31%) [95% CI 19.1 - 45.9] |
Time to CR, median months (range) | 2.95 (1-7.6) | 3.3 (1-7.6) |
Duration of CR, median months [95% CI] | 20.3 [95% CI 3.7 - NR]a | 20.3 (95% CI 5.6 - NR)c |
CR/CRh rate | ||
Response rate, n (%) [95% CI] | 21 (31%) [95% CI 20.6 - 43.8] | 19 (37%) [95% CI 24.1 - 51.9] |
Time to CR/CRh, median months (range) | 3 (1-9.5) | 3.6 (1-9.5) |
Duration of CR/CRh, median months [95% CI] | 14.7 [95% CI 4.6 - NR]a | 14.7 [95% CI 4.6 - NR]c |
Overall response rate | ||
Response rate, n (%) [95% CI] | 34 (51%) [95% CI 38.2–63.2] | 30 (59%) [95% CI 44.2 - 72.4] |
Time to first OR, median months (range) | 1.95 (0.9-7.6) | 1.9 (0.9-7.6) |
Duration of OR, median months [95% CI] | 6.5 [95% CI 3.7 - 21.2]b | 8 [95% CI 4.5 - 21.2]d |
Best overall response, n (%) | ||
CR/CRh/CRi | 26 (39) | 23 (45) |
CR | 18 (27) | 16 (31) |
CRh | 3 (4) | 3 (6) |
CRi | 5 (7) | 4 (8) |
MLFS | 4 (6) | 4 (8) |
PR | 4 (6) | 3 (6) |
Stable disease | 24 (36)e | 15 (29)e |
Progressive disease | 2 (3) | 2 (4) |
Not evaluable/not done | 7 (10) | 4 (8) |